CLARIS-INTERNATIONAL
28.10.2020 07:02:12 CET | Business Wire | Press release
Claris International Inc., an Apple subsidiary and pioneering leader in low-code, today announced the official launch of FileMaker Cloud to EMEA markets. FileMaker Cloud gives EMEA businesses all of the power of the cloud - sharing, rapid deployment, scalability - without compromising on performance or losing connection to the real world of devices, sensors, even offline apps. The result is a future-proof solution that empowers businesses to rapidly create and share intelligent apps with their teams, and integrate them with other popular apps and web services.
“For so many businesses, the global pandemic changed every aspect of their business overnight, which led to a massive boom in both low-code adoption and remote work technologies,” said Brad Freitag, CEO of Claris. “In many ways, Claris was built for this moment. Our commitment to low-code without limits - quickly deploying intelligent apps that both solve and evolve - means the solutions our customers build to deal with today’s changes can serve as their IT backbone going forward. We’re thrilled to finally bring FileMaker Cloud to EMEA as we continue to power the workplace of tomorrow through limitless and scalable low-code solutions.”
Designed to augment its widely adopted Claris Platform, FileMaker Cloud offers localised infrastructure to assist businesses with implementing General Data Protection Regulation (GDPR) and German Bundesdatenschutzgesetz (BDSG) compliance, while also providing a scalable, agile, and adaptable solution to drive IT impact in EMEA. The FileMaker Cloud solution also brings emerging technologies within reach, ready to leverage artificial intelligence (AI), machine learning (ML), digital assistants, Internet of Things, augmented and virtual reality, and whatever comes next.
FileMaker Cloud offers the following capabilities:
- Agility and speed: Ability to rapidly deploy within an organisation without software or hardware. Start creating and sharing custom apps 4x faster.
- Streamlined management: Easily manage users and groups in one secure place, including full tracking, and visibility.
- Privacy, security and support: Provides end-to-end encryption, multi-factor authentication, and dedicated 24/7 support and monitoring by expert teams to ensure premium security and performance.
- Hassle-free infrastructure: Access to fully configured hardware and installed software, as well as automated server maintenance.
- Future-proof scalability: Ability to rapidly scale across departments and entire businesses for fast-paced growth.
- Affordable, set prices: Yearly subscription fee of €41 EUR per month, available for purchase in local currency.
- Certificates: Built-in SSL certificate included with the service.
- Local language support: Access to multiple languages, including French, Italian, German, and Spanish.
For more information or to purchase FileMaker Cloud, please visit store.filemaker.com .
About Claris International Inc.
Claris International Inc. is the creator of the world's leading rapid, low-code development platform, offering a suite of services that empower problem solvers to drive digital transformation in businesses large and small. The company has more than 1.3 million active users globally across SMBs and the Fortune 500. Claris is an Apple subsidiary with an unmatched record of business success of more than 80 consecutive profitable quarters. Claris is headquartered in California with operations worldwide, including London, Paris, Munich, Tokyo, Beijing, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom